aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) shares were up 8.1% during trading on Tuesday . The company traded as high as $6.08 and last traded at $5.82. Approximately 2,277,454 shares changed hands during trading, a decline of 9% from the average daily volume of 2,504,492 shares. The stock had previously closed at $5.38.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on ATYR. Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Wells Fargo & Company lifted their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Finally, Jefferies Financial Group raised their price target on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $23.25.
Check Out Our Latest Report on ATYR
aTyr Pharma Stock Up 2.6%
The company has a market cap of $549.71 million, a price-to-earnings ratio of -7.01 and a beta of 1.01. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The firm's fifty day moving average price is $5.34 and its 200-day moving average price is $4.33.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Sell-side analysts predict that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.
Institutional Investors Weigh In On aTyr Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in ATYR. California State Teachers Retirement System acquired a new position in shares of aTyr Pharma during the 2nd quarter worth about $28,000. Group One Trading LLC acquired a new position in aTyr Pharma in the 4th quarter valued at about $26,000. XTX Topco Ltd grew its stake in aTyr Pharma by 74.9% in the 1st quarter. XTX Topco Ltd now owns 19,556 shares of the company's stock valued at $59,000 after buying an additional 8,374 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in aTyr Pharma in the 2nd quarter valued at about $45,000. Finally, Main Street Financial Solutions LLC grew its stake in aTyr Pharma by 7.0% in the 2nd quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company's stock valued at $728,000 after buying an additional 9,350 shares during the last quarter. 61.72% of the stock is owned by institutional investors.
About aTyr Pharma
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
